The pharmaceutical circulation industry is a link between pharmaceutical and medical device manufacturers and medical institutions at all levels, and plays an important role
in the entire pharmaceutical industry chain.
In recent years, the development of the pharmaceutical circulation industry has been more and more deeply affected
by national laws and regulations and related industry policies.
The state has successively promulgated or revised a number of laws and regulations such as the Drug Administration Law and the Measures for the Administration of Drug Inspection, continuously improving the management standards of pharmaceutical enterprises and putting forward higher requirements
for the standardized operation of pharmaceutical enterprises.
It is worth noting that in the context of the relevant pharmaceutical circulation industry facing greater growth pressure, many pharmaceutical circulation enterprises are beginning to embark on the road
to listing in order to build new projects and supplement liquidity and enhance competitiveness.
For example, on October 8, reports showed that Hunan Hengchang Pharmaceutical Group Co.
, Ltd.
submitted a prospectus
for an initial public offering.
Accordingly, the company intends to sprint to the Shenzhen Stock Exchange GEM IPO listing, the company's initial public offering of shares to be issued is not less than 40.
01 million shares, not less than 10% of the total share capital after the issuance; The shares to be issued are all new shares and do not involve the public offering of shares by shareholders
.
According to the prospectus, Hengchang Pharmaceutical is a pharmaceutical circulation enterprise focusing on serving small and medium-sized chain pharmacies, single pharmacies and primary medical and health institutions
.
The total investment of the proposed investment project is 815 million yuan, and the proposed investment is 771 million yuan, the main investment projects are Hengchang Pharmaceutical Headquarters Base Project, the Big Health Industry Integration Service Online Platform Construction Project and the Supplementary Liquidity Project
.
Prior to Hengchang Pharmaceutical, the same category of enterprise Huaren Health also submitted an IPO prospectus for the ChiNext Board in May 2021, with the intention of raising 600 million yuan
.
It is understood that Huaren Health focuses on the pharmaceutical circulation industry, mainly engaged in pharmaceutical agency, retail and terminal collection and procurement of three major businesses during the reporting period, from 2018 to 2020 and the first half of 2021, the company achieved operating income of about 1.
105 billion yuan, 1.
522 billion yuan, 1.
931 billion yuan and 1.
03 billion yuan
, respectively.
In addition, as early as 2021, the listing ceremony of Dajiaweikang on the GEM was also successfully held
on the morning of December 7.
Industry analysts believe that due to factors such as medical insurance control fees and medical reform, the entire pharmaceutical industry chain has entered a period of transformation and adjustment, and the drug circulation link has also ushered in an accelerated reshuffle
.
In order to cope with this change, pharmaceutical circulation companies have begun to accelerate their listing, to raise more funds to build new projects, new bases and so on
.
It is worth noting that in addition to accelerating the pursuit of listing, in fact, the pharmaceutical circulation sector is promoted by the "dual channel" policy, collection, etc.
, the industry market structure has accelerated its reshaping, and the market share of many enterprises has also increased significantly
.
According to industry statistics, as of May this year, 16 of the 2021 annual reports disclosed by 32 pharmaceutical circulation companies exceeded 10 billion yuan, and 4 companies had revenues of more than 50 billion yuan
.
The industry believes that in the context of the continuous acceleration of the development of the pharmaceutical industry, pharmaceutical circulation enterprises will face more opportunities and challenges, and need to continue to accelerate transformation and upgrading, in order to better grasp the development trend of drug retail chaining, specialization, diversification and specialization, do fine and specialized, bigger and stronger, and meet the needs of the multi-level health consumer market
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
